Tue, Jun 9, 2026
[Archive]
Articles In Press
Back to the articles list |
Back to browse issues page
Hayder Ahmed Sahar Algburi1 
, Ahmad Deylami2 , Hadis Musavi3 , Hossein Mokhtari , Neda Masoumi Qajari4 , Fatemeh Lotfi Asrami5 , Abbas Khonakdar *6
, Ahmad Deylami2 , Hadis Musavi3 , Hossein Mokhtari , Neda Masoumi Qajari4 , Fatemeh Lotfi Asrami5 , Abbas Khonakdar *6
1- 1Department of Clinical Biochemistry and Genetics, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
2- Department of Urology, School of Medicine, Mazandaran University of Medical Sciences
3- Department of Clinical Biochemistry and Genetics, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
4- Genetic biology,Tonekabon Islamic Azad University,Tnekabon,Iran
5- 5Department of Biochemistry, Biophysics, Genetics and Nutrition, School of Medicine Metabolic Disorders Research Center, Golestan University of Medical Sciences
6- Department of Clinical Biochemistry and Genetics, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran & Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Mazandaran University of Medical
2- Department of Urology, School of Medicine, Mazandaran University of Medical Sciences
3- Department of Clinical Biochemistry and Genetics, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
4- Genetic biology,Tonekabon Islamic Azad University,Tnekabon,Iran
5- 5Department of Biochemistry, Biophysics, Genetics and Nutrition, School of Medicine Metabolic Disorders Research Center, Golestan University of Medical Sciences
6- Department of Clinical Biochemistry and Genetics, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran & Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Mazandaran University of Medical
Abstract: (122 Views)
Background: Differentiating Prostate Cancer (PC) from benign prostatic hyperplasia (BPH) remains clinically challenging due to overlapping symptoms and biomarker alterations. This study compared biochemical, hematological, and inflammatory markers in both conditions to assess their potential diagnostic value.
Methods: A cross-sectional study was performed on 40 patients with PC and 120 patients with benign prostatic hyperplasia. The measurement of biochemical parameters included complete blood count, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) and total and free prostate-specific antigen (PSA). The process involved statistical comparisons, ROC analysis, and correlation tests
Results: Compared to BPH, patients with PC had significantly higher PSA (free and total), CRP, and lymphocyte counts (All p<0.05). Despite the diagnostic utility of PSA and inflammatory markers (AUCs 0.68-0.80), hematological parameters in isolation were not strong discriminators (AUCs<0.50), and a combined biomarker strategy would be more effective in clinical discrimination.
Conclusion: Detection of PC from BPH is accurately achieved by examining elevated free and total PSA levels, along with increased systemic inflammation, as indicated by CRP. The independent discriminant value of hematologic parameters is limited despite significant diversity between groups.. A combination of PSA and inflammatory markers in a two-biomarker strategy can improve clinical discrimination and reduce inappropriate therapy.
Methods: A cross-sectional study was performed on 40 patients with PC and 120 patients with benign prostatic hyperplasia. The measurement of biochemical parameters included complete blood count, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) and total and free prostate-specific antigen (PSA). The process involved statistical comparisons, ROC analysis, and correlation tests
Results: Compared to BPH, patients with PC had significantly higher PSA (free and total), CRP, and lymphocyte counts (All p<0.05). Despite the diagnostic utility of PSA and inflammatory markers (AUCs 0.68-0.80), hematological parameters in isolation were not strong discriminators (AUCs<0.50), and a combined biomarker strategy would be more effective in clinical discrimination.
Conclusion: Detection of PC from BPH is accurately achieved by examining elevated free and total PSA levels, along with increased systemic inflammation, as indicated by CRP. The independent discriminant value of hematologic parameters is limited despite significant diversity between groups.. A combination of PSA and inflammatory markers in a two-biomarker strategy can improve clinical discrimination and reduce inappropriate therapy.
Type of Study: Original Research Article |
Subject:
Clinical Medicine
Received: 2025/08/22 | Accepted: 2026/04/12
Received: 2025/08/22 | Accepted: 2026/04/12
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright Policy
Journal of Advances in Medical and Biomedical Research by Farname Inc. is licensed under CC BY-NC 4.0
